I'm LongbridgeAI, I can summarize articles.REGENXB priced its public offering of 10,003,889 common shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999. The underwriters exercised their full over-allotment option for an additional 1,667,250 shares. Net proceeds are expected to be approximately $107.8 million after deducting discounts and expenses. The offering is expected to close on July 20, 2026.
REGENXB priced public offering of 10,003,889 common shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999.
Key Highlights:
- Underwriting agreement sold 10,003,889 common shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999.
- Underwriters exercised full 30-day option for 1,667,250 additional shares; offering expected to close July 20, 2026.
- Net proceeds expected to be approximately $107.8 million after underwriting discounts, commissions and expenses.
- Pre-funded warrants exercisable at $0.0001 per share, exercisable any time and do not expire; holders have no stock rights until exercised.
- Offering made under effective Form S-3 registration; underwriting agreement contains customary terms and indemnities.
Original SEC Filing: REGENXBIO Inc. [ RGNX ] - 8-K - Jul. 20, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.